YSYun-Jie Song

Yun-Jie Song

*This is an algorithmically generated author record based on publicly available information.

Yun-Jie Song has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Aiwen Zheng

    Cancer Hospital of the University of Chinese Academy of Science

    1 shared publication
  • Chen-Jie Tao

    Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity, Shanghai, China

    1 shared publication
  • Cheng Lou

    Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity, Shanghai, China

    1 shared publication
  • Chuang Qi

    Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development, Nanjing, China

    1 shared publication
  • Dong-Sheng Chen

    Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development, Nanjing, China

    1 shared publication
  • Dongsheng Chen

    State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study

    by Yue Liu, Jin-Jie He, Sheng Chen, Yun-Jie Song, Jin-Lin Du, Yu-Ping Zhu, Dong-Sheng Chen, Wang-Long Deng, Ying Yuan, Ke-Feng Ding

    Circulating tumor DNA (ctDNA) derived from blood samples can serve as a minimally invasive, real-time indicator of tumor burden and treatment response in metastatic colorectal cancer. This study evaluated the association between baseline ctDNA levels and changes in ctDNA during treatment with response and survival outcomes in the phase II ALTER-C-002 trial, which investigated first-line anlotinib combined with capecitabine and oxaliplatin in patients with rat sarcoma (RAS) and B-Raf proto-oncogene (BRAF) wild-type metastatic colorectal cancer. In this post-hoc biomarker analysis, plasma samples were collected at baseline, near the best radiologic response (C1), and at the timepoint closest to disease progression or last follow-up (C2). These samples were analyzed using a 90-gene next-generation sequencing (NGS) panel, with ctDNA abundance quantified as maximum somatic allele frequency (MSAF), where MSAF <0.001 indicated ctDNA negativity. Biomarker data were obtained for 26 patients, 25 of whom had measurements at all three timepoints. Notably, baseline MSAF was higher in patients with liver-only metastasis (p=0.017). MSAF decreased significantly at C1 compared to baseline (p<0.001) and increased at C2 relative to C1 in patients exhibiting progressive disease (PD) (p<0.001); additionally, higher MSAF at C1 was associated with subsequent PD at C2 (p=0.015). All patients who tested ctDNA-negative at C1 achieved an objective response, and ctDNA negativity at this timepoint correlated with longer progression-free survival (PFS) (p=0.012) and overall survival (OS) (p=0.006) compared to ctDNA-positive patients. Furthermore, KRAS/BRAF mutations detected in ctDNA were linked to shorter PFS and OS (all p<0.05). In conclusion, baseline ctDNA burden and early ctDNA clearance may function as prognostic and on-treatment biomarkers of therapeutic efficacy in metastatic colorectal cancer, warranting prospective validation.

  • Prediction of Patients With High-Risk Osteosarcoma on the Basis of XGBoost Algorithm Using Transcriptome and Methylation Data From SGH-OS Cohort

    by Weisong Zhao, Huanliang Meng, Zhenwu Dai, Lulu Zhang, Zhiwei Cheng, Yunjie Song, Wenyuan Xu, Zhuoying Wang, Kai Tian, Yafei Jiang, et al.

    PURPOSE: Osteosarcoma (OS) is the most prevalent primary malignant bone sarcoma, characterized by its high rates of metastasis and mortality. In our previous multiomics analysis of the Shanghai General Hospital OS (SGH-OS) cohort, we identified four distinct OS subtypes, each with unique molecular characteristics and clinical outcomes. Of particular importance was the identification of the MYC-driven subtype, which exhibited the poorest prognosis and was referred to as high-risk OS. A diagnostic tool is needed for clinicians to identify high-risk OS in advance. The purpose of this study is to develop a classifier capable of accurately predicting the high-risk OS subtype using transcriptome and methylation data. METHODS: In this study, using eXtreme Gradient Boosting (XGBoost) with Bayesian optimization, we developed a classification model by integrating transcriptome and methylation data from our internal SGH-OS cohort. We further validated the model's predictive performance with the external TARGET-OS cohort. RESULTS: Using the XGBoost algorithm, we developed a classifier incorporating nine genes (ARHGAP9, CADM1, CPE, DUSP3, FGFR1, GALNT3, IGF2BP3, KIF26A, ZFP3). In our internal cohort, the classifier exhibited excellent predictive performance, with an area under the receiver operating characteristics curve (AUC) of 0.999 and an overall accuracy of 0.989. Furthermore, the classifier successfully stratified two groups with distinct survival outcomes in the external TARGET-OS cohort. Notably, our analysis revealed a positive correlation between IGF2BP3 and MYC signaling pathways, highlighting IGF2BP3 as a potential therapeutic target in high-risk OS. CONCLUSION: Our classifier demonstrated excellent predictive performance in identifying patients with high-risk OS, offering the potential to enhance treatment decision making and optimize patient management strategies.


  • Open Access

    Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer

    by Tian-Mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-Jie Tao, Xi-Yun Chen, Qin Han, Zhuo Cheng, Pei-Pei Shang, Yu-Long Dong, et al.

    The prognosis of biliary tract cancer (BTC) remains unsatisfactory. This single-arm, phase II clinical trial (ChiCTR2000036652) investigated the efficacy, safety, and predictive biomarkers of sintilimab plus gemcitabine and cisplatin as the first-line treatment for patients with advanced BTCs. The primary endpoint was overall survival (OS). Secondary endpoints included toxicities, progression-free survival (PFS), and objective response rate (ORR); multi-omics biomarkers were assessed as exploratory objective. Thirty patients were enrolled and received treatment, the median OS and PFS were 15.9 months and 5.1 months, the ORR was 36.7%. The most common grade 3 or 4 treatment-related adverse events were thrombocytopenia (33.3%), with no reported deaths nor unexpected safety events. Predefined biomarker analysis indicated that patients with homologous recombination repair pathway gene alterations or loss-of-function mutations in chromatin remodeling genes presented better tumor response and survival outcomes. Furthermore, transcriptome analysis revealed a markedly longer PFS and tumor response were associated with higher expression of a 3-gene effector T cell signature or an 18-gene inflamed T cell signature. Sintilimab plus gemcitabine and cisplatin meets pre-specified endpoints and displays acceptable safety profile, multiomics potential predictive biomarkers are identified and warrant further verification.


  • Open Access

    Benchmarking the HLA typing performance of three HLA assays and seven NGS-based HLA algorithms

    by Ping Liu, Aiwen Zheng, Yu Gong, Yunjie Song, Yanan Chen, Yizhou Ye, Xiao Liu, Fugen Li, Hua Dong, Rui Meng, et al.

    Background With the great progress made recently in NGS (Next Generation Sequencing) technology, sequencing accuracy and throughput have increased, while the cost for data has decreased. Various HLA (Human Leukocyte Antigen) typing algorithms and assays have been developed and have begun to be used in clinical practice. However, there is no systematic benchmarking to evaluate the HLA typing performance of different HLA assays and algorithms. In this study, we compared the HLA typing performance of three HLA assays and seven NGS-based HLA algorithms and assessed the impact of sequencing depth and length on HLA typing accuracy. Results Seven HLA typing algorithms at 4- and 6-digit allele levels were compared on three different assays in terms of accuracy, read depth and read length. The algorithms HLA-HD and HISAT-genotype showed the highest accuracy at both 2- and 4-digit resolution, followed by HLAscan. We designed a capture-based HLA assay, which showed comparable or even better performance compared with WES (Whole Exome Sequencing). In the depth evaluation, the sequencing data were down-sampled from 500X to 10X based on the depth of HLA genes. We found that the minimal depth was 100X for HLA-HD and HISAT-genotype to obtain more than 90% HLA typing accuracy at the 6-digit allele level. The accuracy of all three algorithms did not change when the read length decreased from 150 bp to 76 bp. Conclusion Although HISAT-genotype and HLA-HD may need more computing resources, we recommend using them for NGS-based HLA genotyping because of their higher accuracy and robustness to sequencing depth and read length. We propose that the minimal sequence depth for obtaining more than 90% HLA typing accuracy at the 6-digit allele level is 100X. Besides, targeting capture-based NGS HLA typing may be more suitable than WES in clinical practice due to its lower sequencing cost and higher HLA sequencing depth.